KRAS and colorectal cancer: Yang et al. established a platform-weighted chemi-luminescent membrane array and demonstrated detection of CTCs harboring K-ras mutations in the blood of colorectal cancer patients which could potentially aid to identify K-ras wild type patients who are more likely to benefit from treatment with EGFR inhibitors [45].